South Korea vs Latin America and the Caribbean: Percentage of bloodstream infection due … methicillin-resistant
South Korea
45.7%
in 2022
Latin America and the Caribbean
39.0%
in 2022
South Korea rank
13th
Latin America and the Caribbean rank
10th
Percentage of bloodstream infection due … methicillin-resistant over time
- South Korea
- Latin America and the Caribbean
How they compare
South Korea currently reports 45.7% against 39.0% in Latin America and the Caribbean, a difference of 6.7%.
That makes South Korea's figure about 1.2 times Latin America and the Caribbean's.
Across all 6 years both countries report, South Korea has been ahead every year.
South Korea ranks 13th and Latin America and the Caribbean ranks 10th of 50 countries.
South Korea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | South Korea | Latin America and the Caribbean | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 49.7% | 39.2% | 10.4% | South Korea |
| 2020s | 46.2% | 40.5% | 5.7% | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to methicillin-resistant, South Korea or Latin America and the Caribbean?
- South Korea, at 45.7% against 39.0% in Latin America and the Caribbean as of 2022.
- What is the difference in percentage of bloodstream infection due to methicillin-resistant between South Korea and Latin America and the Caribbean?
- 6.7%, with South Korea ahead.
- How many years of comparable data are there for South Korea and Latin America and the Caribbean?
- 6 years are reported by both, from 2017 to 2022.
- How do South Korea and Latin America and the Caribbean rank globally for percentage of bloodstream infection due to methicillin-resistant?
- South Korea ranks 13th and Latin America and the Caribbean ranks 10th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.